Recent BioUtah News & Events

The award supports innovative, high-impact research aimed at advancing the prevention, diagnosis, and treatment of breast cancer.

Survival benefit is concentrated in participants with NfL biomarker response.

In-vitro studies confirmed revolutionary therapy successfully disguised liver cancer cells as virally infected cells and activated pre-existing human antiviral Killer T-cells.

Teledyne will acquire all of the outstanding common shares of Varex for $18.90 per share, payable in cash.

BioUtah and BYU’s College of Life Sciences hosted the annual BYU/BioUtah Networking Lunch on August 7 at BYU’s Life Sciences Building in Provo. Nearly 100 people attended out of more than 100 registrants, bringing together life sciences companies from across the state with BYU’s research and tech transfer community. The lunch is one piece of […]

STAT delivers U.S. Government Advocacy for Foreign Investment & Concession Projects

For more than 30 years, AIM has been Europe’s most successful growth market.

Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow.

The Recursion option follows several years of work building what Recursion calls “maps of biology.“

Round brings total capital raised to over $240M.

Funding Brings Total Raised to $47.5M as Demand Grows for Better Infrastructure to Support Biopharma

Submission includes a concurrent CLIA Waiver by Application for use of the test on the Co-Dx PCR Pro® instrument in decentralized point-of-care settings.

A company still awaiting its first FDA clearance just structured a capital raise around the urgency of that wait. On July 30, 2026, Co-Diagnostics, Inc. entered into a warrant inducement agreement with existing warrant holders, convincing them to exercise warrants early in exchange for new warrants at revised terms. The transaction is straightforward on its […]

ARUP Laboratories observed Cyclospora positivity rates increase from very low levels to unprecedented levels within a short period of time.

Investment will support commercialization of GPX and ULTRA Embolic Devices and development of IMPASS neurovascular platform.

Canyon Labs strengthens its commitment to medical device manufacturers with strategic, direct-access leadership investments.

Southern Metrics is led by Chris Lyons, its Chief Executive Officer, an experienced medical technology executive and strategic advisor who has served on the SINTX Board of Directors since April 2025.

Independent industry recognition highlights the Company’s revolutionary immunotherapy platform and growing momentum in precision cancer treatment.

Global medical device quality executive brings more than 30 years of experience building high-performing organizations, advancing quality excellence and supporting scalable growth.

Company also completes proof of concept for the first blood-borne test for Ebola on Co-Dx PCR Pro ® instrument.

ReNU syndrome was discovered in 2024 and there are no medicines approved for the condition.

Company completes design and in-vitro validation of a single Smart mRNA that disguises cancer as multiple viral infections simultaneously to activate pre-existing T-cell immunity.

Preclinical data show HT-4253 reduces neuroinflammation and tau pathology; a second details a Phase 2a biomarker trial in pre-symptomatic APOE4 carriers via UAE genomics.

Purchase orders from multiple contract manufacturing customers have a combined value of more than $3.2M.

CAP accreditation is widely recognized as a mark of laboratory quality and operational excellence.

Brand consolidation strengthens Renew’s ability to move advanced molecular technologies from discovery to clinical implementation.

KyphoLift is gaining attention as hospitals and imaging centers prepare for federal accessibility requirements.

Marks an important milestone with a ribbon-cutting ceremony celebrating the completion of an expansive new distribution center.

Trial Reports 99% Successful Occlusion of Flow with 40 Investigators Delivering the New Embolic Through 20 Different Catheters.

Workshop brings together national TB programs, researchers, donors, and technical agencies from 21 countries to advance implementation of WHO-recommended near-point-of-care diagnostics.

INTEGUMENT-INFANT showed 49.1% achieving vIGA-AD clear/almost clear at week 4 and 27.3% meeting vIGA-AD Success, alongside rapid pruritus improvement.

resentation will highlight recent scientific advances and future opportunities to accelerate discovery and development of medicines for neurodegenerative diseases.